NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer NDTV Profit’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Motilal Oswal Report
Marico Ltd. reported an in-line revenue growth with a marginal beat on Ebitda. Domestic revenue was flat owing to the impact of price cuts and an unchanged volume trend.
A sequential improvement was noted in urban areas, while the rural recovery was slow. However, the demand environment remained muted during the quarter.
Domestic revenue is likely to improve in the ensuing quarters owing to a gradual volume recovery and a low price cut impact. We model an 8% revenue compound annual growth rate during FY24-26 for the domestic business.
Gross margin hit a 23-quarter high of 51.3% in Q3 FY24, driven by softer input costs. Consequently, management raised its Ebitda margin guidance by ~250 basis point to 21% for FY24.
We model a 21-22% Ebitda margin during FY24-26, as we build a similar gross margin of 51% while assuming normalisation in Ad spending.
We value the stock based on 45 times December-25E earnings per share to arrive at our target price of Rs 625. We reiterate our 'Buy' rating on Marico. It remains a play on rural recovery.
Click on the attachment to read the full report:
Also Read: Marico Q3 Results Review - Muted Demand, Lacks Triggers In Near Term: Prabhudas Lilladher
DISCLAIMER
This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
RECOMMENDED FOR YOU
![](https://images.assettype.com/bloombergquint/2024-08-23/t2p0rzli/pexels-tima-miroshnichenko-7034131.jpg?rect=0%2C0%2C3500%2C1969&auto=format%2Ccompress&format=webp&w=75)
Pharma Sector Q1 Results Review - Select Bets To Continue To Perform: DRChoksey
![timelogo](/images/amp-time.png)
![](https://images.assettype.com/bloombergquint/2020-10/8034c97a-f5af-45a5-a113-3e39c4226338/Marico_Logo__002_.png?rect=0%2C0%2C3500%2C1969&auto=format%2Ccompress&format=webp&w=75)
Marico Q1 Results Review - Growth Outlook Turns More Positive; Margins Likely Peak Out: Systematix
![timelogo](/images/amp-time.png)
![](https://images.assettype.com/bloombergquint/2022-11/a0e1bd8a-0b87-4828-bc1e-b060047ec28e/Marico_Ltd__s_products___Source_Company_website_.png?rect=0%2C0%2C3500%2C1969&auto=format%2Ccompress&format=webp&w=75)
Marico Q1 Results Review - Margins Inline With Estimate; Maintain Accumulate: Dolat Capital
![timelogo](/images/amp-time.png)
![](https://images.assettype.com/bloombergquint/2023-02/5290c152-935d-45c5-9bac-4c924469b481/Parachute_oil_manufactured_by_Marico_Ltd___Source_Company_website_.png?rect=0%2C0%2C3500%2C1969&auto=format%2Ccompress&format=webp&w=75)
Marico Q1 Results Review - Core Portfolio Tepid, Peaked Out Margins: Prabhudas Lilladher
![timelogo](/images/amp-time.png)